ArticleCureus2025
Conservative Management of Coronary Artery Disease With Ectasia in Antiphospholipid Syndrome-Associated Thrombocytopenia: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the fact that cardiovascular involvement in antiphospholipid syndrome (APS) is less common, it carries serious complications, especially in preexisting coronary artery disease (CAD) and ectasia. We present a 55-year-old man diagnosed with APS aggravated by secondary immune thrombocytopenic purpura. One year later, he presented with an acute myocardial infarction in the context of thrombocytopenia, which was challenging. A coronary angiogram revealed a total distal left anterior descending artery occlusion and coronary artery ectasia with diffuse atherosclerosis. Conservative management was chosen due to lower procedural success and higher incidence of complications, and his follow-up showed no functional impairment (stationary left ventricular ejection fraction) and compliance with heart-remodifying medications. Thus, the management of CAD in such patients remains very challenging and requires cautious treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.